Comprehensive medication guide to Zurzuvae including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0 with the Zurzuvae Savings Card for eligible commercially insured patients; Medicaid patients typically pay $0–$10 copay; Medicare Part D patients face Tier 5 specialty cost-sharing (no savings card allowed). Prior authorization is typically required.
Estimated Cash Pricing
$15,900–$18,286 for a full 14-day treatment course at cash price; Zurzuvae is only available at specialty pharmacies and no generic exists. The manufacturer's savings card can reduce cost to $0 for eligible commercially insured patients.
Medfinder Findability Score
45/100
On this page
Zurzuvae (zuranolone) is a prescription medication approved by the FDA in August 2023 as the first and only oral treatment specifically indicated for postpartum depression (PPD) in adults. It is manufactured by Sage Therapeutics in partnership with Biogen and became commercially available in December 2023.
Zurzuvae belongs to a new class of medications called neuroactive steroids (NAS). Unlike SSRIs and SNRIs, which target the serotonin system, Zurzuvae works on the brain's GABA-A receptors—the primary inhibitory signaling pathway. This novel mechanism enables it to work much faster than traditional antidepressants, with clinical benefits observed as early as Day 3 of treatment.
The recommended dose is 50 mg taken once daily in the evening with a fatty meal for 14 consecutive days. Zurzuvae is a Schedule IV (C-IV) controlled substance and is only available through authorized specialty pharmacies—not at retail locations like CVS or Walgreens.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Zurzuvae works by targeting the brain's GABA (gamma-aminobutyric acid) system. GABA is the primary inhibitory neurotransmitter—it dampens neural activity to promote calm and mood stability. Zuranolone, the active ingredient in Zurzuvae, is a synthetic analog of allopregnanolone, a metabolite of the hormone progesterone that peaks during pregnancy and drops sharply after delivery.
This sudden post-delivery drop in allopregnanolone disrupts GABA-A receptor function and is thought to trigger PPD. Zurzuvae acts as a positive allosteric modulator (PAM) of GABA-A receptors—essentially enhancing the brain's natural GABA signaling to help restore the inhibitory balance disrupted after childbirth.
Unlike SSRIs that require 2–4 weeks to reach full therapeutic effect, Zurzuvae's direct action on GABA-A receptors allows it to produce clinically significant improvement in PPD symptoms as early as Day 3. Benefits were sustained through Day 45 in Phase 3 clinical trials (SKYLARK and ROBIN studies).
50 mg — capsule (two 25 mg capsules)
Recommended adult dose: take once daily in the evening with a fatty meal for 14 consecutive days
20 mg — capsule
Lower strength available for dose reduction per prescriber guidance
25 mg — capsule
Standard unit strength used for the recommended 50 mg dose (2 capsules)
30 mg — capsule
Available for intermediate dosing as directed by prescriber
Zurzuvae is not on the FDA's official drug shortage list, but finding it is genuinely challenging due to its specialty pharmacy-only distribution model. It cannot be stocked or dispensed at retail pharmacies. Instead, it is available only through a select network of authorized specialty pharmacies that ship the medication directly to patients.
Additional access barriers include prior authorization requirements from most insurers, step therapy policies at some plans, and the complexity of the specialty pharmacy submission workflow. In practice, obtaining Zurzuvae typically takes 3–14 days from prescription submission to delivery—longer if prior authorization encounters delays.
To find which specialty pharmacies can fill your Zurzuvae prescription, use medfinder. medfinder contacts specialty pharmacies on your behalf and sends you the results by text—saving hours of phone calls and callback loops.
Because Zurzuvae is a Schedule IV (C-IV) controlled substance, it can be prescribed by any licensed healthcare provider with DEA prescribing authority. Prescribers must be familiar with the specialty pharmacy submission workflow, as Zurzuvae cannot be dispensed at retail pharmacies.
Zurzuvae can be prescribed via telehealth. Since the medication is already delivered by specialty pharmacy mail, telehealth-plus-specialty-pharmacy is a fully remote pathway that works well for new mothers with limited mobility. Several telehealth platforms specialize in postpartum mental health and have experience with the Zurzuvae specialty pharmacy submission workflow.
Yes. Zurzuvae (zuranolone) is classified by the DEA as a Schedule IV (C-IV) controlled substance. This classification reflects the fact that zuranolone has recognized potential for abuse, misuse, physical dependence, and addiction—at a level comparable to benzodiazepines such as alprazolam (Xanax), which is also Schedule IV.
As a Schedule IV medication, Zurzuvae can be prescribed by any licensed healthcare provider with DEA prescribing authority, including physicians, nurse practitioners, and physician assistants with appropriate registration. State and federal laws limit how Schedule IV prescriptions can be refilled or transferred, and the controlled substance status adds additional steps to the specialty pharmacy dispensing process.
Patients with a history of drug abuse or substance use disorders may be at greater risk of dependence and should discuss this with their prescriber before starting Zurzuvae. Physical dependence is possible even over the short 14-day course. Zurzuvae should be kept in a secure location and should not be shared with others.
The following common side effects were reported in ≥5% of patients in clinical trials and at a higher rate than placebo:
Know what you need? Skip the search.
Sertraline (Zoloft)
Most commonly prescribed SSRI for PPD off-label; generic available from $8-$15/month; considered safe during breastfeeding; takes 2-4 weeks to work vs. Zurzuvae's Day 3 onset
Escitalopram (Lexapro)
SSRI used off-label for PPD with favorable tolerability; generic available; considered safe during breastfeeding; good option when anxiety is a prominent PPD symptom
Venlafaxine (Effexor XR)
SNRI used off-label for PPD, especially helpful when anxiety and fatigue are prominent; generic available; requires gradual tapering to discontinue
Fluoxetine (Prozac)
SSRI option for PPD; very affordable generic ($4-$10/month); long half-life requires caution in breastfeeding in very young infants; activating—may worsen initial anxiety
Prefer Zurzuvae? We can find it.
Alcohol (ethanol)
majorSignificantly increases psychomotor impairment; clinical studies confirmed worsening performance on psychomotor tests when combined with Zurzuvae. Avoid alcohol entirely during the 14-day treatment course.
Benzodiazepines (alprazolam, lorazepam, clonazepam)
majorAdditive CNS depression; clinical study with alprazolam confirmed significantly increased psychomotor impairment. Avoid if possible; consider dose reduction if combination unavoidable.
Opioids (oxycodone, hydrocodone, morphine, codeine)
majorAdditive CNS and respiratory depression; significantly increases risk of excessive sedation and respiratory compromise. Avoid combination.
Tricyclic antidepressants (amitriptyline, nortriptyline)
moderateAdditive CNS depression and sedation. Monitor closely if combination cannot be avoided.
CYP3A4 inhibitors (fluconazole, ketoconazole, clarithromycin, ritonavir)
moderateIncrease zuranolone exposure by slowing its metabolism. Dose reduction of Zurzuvae is recommended when used with strong CYP3A4 inhibitors.
Sleep medications (zolpidem, eszopiclone)
moderateAdditive CNS depression; both act on GABA-A receptors like Zurzuvae. Significantly increases sedation and fall risk.
St. John's Wort
moderateCYP3A4 inducer that may reduce zuranolone blood levels and reduce effectiveness. Avoid during Zurzuvae treatment.
Zurzuvae represents a genuine breakthrough for postpartum depression treatment—the first oral, PPD-specific medication with a rapid onset mechanism targeting the hormonal disruption that causes PPD. Its ability to produce meaningful improvement as early as Day 3 sets it apart from every other antidepressant available.
However, access remains a significant challenge. Specialty pharmacy-only distribution, prior authorization requirements, controlled substance regulations, and high list price create real barriers for many patients—particularly those without commercial insurance or those in rural areas with limited specialty pharmacy infrastructure. With the 2025 withdrawal of Zulresso (brexanolone) from the market, Zurzuvae is now the only FDA-approved PPD-specific medication available, making access advocacy more important than ever.
If you're struggling to find Zurzuvae at a specialty pharmacy, medfinder contacts specialty pharmacies on your behalf and sends results by text. You can also call Sage Central at 1-844-987-9882 for direct patient support, savings card enrollment, and free drug program access if you're uninsured.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
Real-time availability
Medfinder is actively checking pharmacy inventory for Zurzuvae. We don't publish a number until we have enough verified pharmacy checks to be accurate — start a search and our team confirms current availability near you, usually within 24 hours.
ChatGPT
Claude
Gemini